← Latest news 
Moderna revenue beats estimates as international COVID vaccine sales surge
Business
Published on 1 May 2026
Forecast warns of a softer quarter ahead
Moderna’s first-quarter revenue topped expectations, powered largely by strong international COVID-19 vaccine sales. While the company expects lower-than-anticipated revenue in Q2, it is betting on longer-term growth, targeting a major slice of Europe’s respiratory vaccine market. Its mCombriax launch is planned for 2027, shifting investor focus beyond COVID.
- Moderna’s Q1 revenue beat estimates on overseas COVID vaccine strength
- The company’s Q2 forecast points to softer revenue than expected
- mCombriax launch in 2027 targets Europe’s respiratory vaccine market
- Investors are turning attention to Moderna’s pipeline beyond COVID
Read the full story at The Economic Times
This summarization was done by Beige for a story published on 
The Economic Times